COMPARISON OF TREATMENT PERSISTENCE IN THE REAL-WORLD USE OF NOVEL ORAL ANTICOAGULANTS AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

As oral anticoagulation reduces thromboembolic stroke risk in patients with atrial fibrillation, it is important that patients continue therapy. With the introduction of novel oral anticoagulants (NOACs) in Europe, clinicians and payers are interested in real-world data comparing persistence between